logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea Therapeutics Q4 Loss Per Share Narrows

Chelsea Therapeutics International, Ltd. (CHTP) reported a fourth-quarter net loss of $12.5 million or $0.20 per share versus a net loss of $12.4 million or $0.25 per share for the comparable period in 2010.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.32 per share for the quarter. Analysts' estimates typically exclude special items.

Research and development expenses for the quarter were $7.7 million, compared to $10.2 million for the same period in 2010. The decrease in research and development expense was primarily the result of the completion of clinical trials and the associated decrease in drug development costs.

Selling, general and administrative (SG&A) expenses were $4.8 million compared to $2.3 million for the same period in 2010. The increase in SG&A expense during the quarter is primarily the result of costs associated with pre-launch sales and marketing initiatives including market research, promotional preparations and the addition of key personal working on launch preparations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Google has been fined a hefty 2.42 billion euros or $2.7 billion by the European Commission for breaching EU antitrust rules. The Commission ruled that Google has abused its market dominance as a search engine by giving illegal advantage to its own comparison shopping service. Japanese game maker Nintendo announced its plans to launch Super NES Classic Edition, the standalone mini console, which will feature 21 pre-installed classic games. The Mini 16-Bit System is expected to hit the stores on September 29 for $79.99. Best Inc., a 23.4 percent owned by e-commerce major Alibaba Group, filed for Initial Public Offering in the U.S. According to the filing, Best expects to offer $750 million american depository shares.
comments powered by Disqus
Follow RTT